6696.TWO Lin BioScience Inc.
- Market cap
- TWD 120B
- P/E
- -
- P/B
- 12.41x
- ROE
- -12.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6696.TWO undervalued?
Graham numberThe Graham number of Lin BioScience Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lin BioScience Inc. fundamental analysis
No fundamental analysis for Lin BioScience Inc. yet.
Lin BioScience Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lin BioScience Inc.
Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor …
Full company profileLin BioScience Inc. financial statements
Lin BioScience Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Gross Profit | -4.31M | -4.08M | -4.39M | -11.2M | -17.9M | -20.2M | - |
| Operating Income | -238M | -197M | -338M | -445M | -1.10B | -1.46B | -2.86B |
| EBITDA | -234M | -170M | -486M | -466M | -1.07B | -1.45B | -2.61B |
| Net Income | -235M | -152M | -435M | -314M | -687M | -744M | -1.36B |
| EPS | -3.87 | -2.39 | -6.23 | -4.37 | -9.23 | -9.47 | -1.65 |
| Balance Sheet | |||||||
| Total Assets | 249M | 1.22B | 923M | 1.85B | 3.60B | 5.53B | 25.4B |
| Total Liabilities | 106M | 309M | 470M | 116M | 168M | 173M | 291M |
| Shareholders' Equity | 142M | 912M | 542M | 1.23B | 2.14B | 2.85B | 10.7B |
| Cash & Short-term Investments | 117M | 1.09B | 807M | 1.65B | 3.26B | 5.21B | 11.9B |
| Total Debt | 67.9M | 5.15M | 2.24M | 46.5M | 42.9M | 34.0M | - |
| Cash Flow | |||||||
| Operating Cash Flow | -210M | -181M | -290M | -361M | -1.01B | -1.02B | -1.44B |
| Capital Expenditure | 2.34M | 573K | 2.12M | 22.4M | 1.97M | 7.35M | 8.18M |
| Free Cash Flow | -212M | -181M | -292M | -383M | -1.01B | -1.03B | -1.45B |
| Ratios | |||||||
| ROE | -165.9% | -16.6% | -80.3% | -25.4% | -32.2% | -26.1% | -12.7% |
| ROA | -94.6% | -12.5% | -47.1% | -16.9% | -19.1% | -13.5% | -5.4% |
| Debt to Equity | 0.48x | 0.01x | 0.00x | 0.04x | 0.02x | 0.01x | - |
What these items mean
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lin BioScience Inc. dividends
Lin BioScience Inc. has not paid dividends in the last 7 fiscal years.
Last stock split: 10000:1000 on Aug 20, 2026.
Who owns Lin BioScience Inc.
- Insiders 0.00%
- Institutions 0.13%
- Public & others 99.87%
- Shares outstanding 829M
- Free float 639M
Lin BioScience Inc. company profile
- Company name
- Lin BioScience Inc.
- Ticker
- 6696.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 68, Zhongxiao East Road, Taipei, Taiwan, 110
- Phone
- 886 2 8780 5008
- Website
- linbioscience.com
About Lin BioScience Inc.
Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an first-in-class anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes. Lin BioScience, Inc. is headquartered in Taipei, Taiwan.
Lin BioScience Inc. management
3- Dr. Zhengqi Wang M.B.A., Ph.D.President, CSO & Director
- Ms. Serena ChenChief Financial Officer
- Guan Shan ChenAccounting Supervisor